FDA approves AbbVie’s Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data.
FDA Expands AbbVie’s Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED)
Where Today's News Shapes Tomorrow
